Biosynex risk profile
68 Stretched several inputs deteriorating together
Measured 21 October 2026 from ALBIO's filed statements. Recomputed nightly.
68 (Stretched), driven by Cash conversion at 98, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 85 | Acute | Volatile | One-year price volatility — 90.2% |
| Operating pressure | 82 | Acute | Worsening | Costs outgrowing revenue — +21.2 percentage points |
| Cash conversion | 98 | Acute | Stable | Capital spending against operating cash — -0.46x |
| Leverage and coverage | 86 | Acute | Easing | Net debt to EBITDA — 44.44x |
| Competitive position | 43 | Elevated | Stable | Revenue-growth gap against peers — -58.4 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.